Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc is positioned favorably in the pharmaceutical market with its innovative pipeline, particularly emphasizing Buntanetap, which has the potential to modify disease progression in neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's strategic alignment with the FDA suggests a clear pathway toward filing a New Drug Application (NDA), contingent upon successful completion of clinical trial phases that could subsequently expand indications based on emerging data. Furthermore, the ongoing trials, including the planned Phase 2 trial for ANVS405, illustrate a commitment to advancing their research and development efforts, which could enhance their competitive advantage in addressing significant medical needs within this therapeutic area.

Bears say

Annovis Bio Inc faces significant financing risks due to its limited cash runway, which may necessitate dilutive capital raising activities that could adversely affect shareholder value. The company's pipeline is centered on challenging neurodegenerative diseases, particularly Alzheimer's and Parkinson's, where trial failures related to efficacy and safety are prevalent, further complicating its development efforts. Additionally, the potential lack of FDA approval for its drug filings, combined with the risk of unsuccessful product launches and intense competition, heightens the uncertainty surrounding the company's commercial prospects.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.